These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18536551)

  • 1. Phase 0 clinical trials: conceptions and misconceptions.
    Kummar S; Rubinstein L; Kinders R; Parchment RE; Gutierrez ME; Murgo AJ; Ji J; Mroczkowski B; Pickeral OK; Simpson M; Hollingshead M; Yang SX; Helman L; Wiltrout R; Collins J; Tomaszewski JE; Doroshow JH
    Cancer J; 2008; 14(3):133-7. PubMed ID: 18536551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploratory IND: a new regulatory strategy for early clinical drug development in the United States.
    Sarapa N
    Ernst Schering Res Found Workshop; 2007; (59):151-63. PubMed ID: 17117721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications.
    Karara AH; Edeki T; McLeod J; Tonelli AP; Wagner JA
    J Clin Pharmacol; 2010 Apr; 50(4):380-91. PubMed ID: 20097935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
    Doroshow JH; Parchment RE
    Clin Cancer Res; 2008 Jun; 14(12):3658-63. PubMed ID: 18559579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
    Senderowicz AM
    Clin Cancer Res; 2010 Mar; 16(6):1719-25. PubMed ID: 20215544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging exploratory investigational new drug studies to accelerate drug development.
    Jacobson-Kram D; Mills G
    Clin Cancer Res; 2008 Jun; 14(12):3670-4. PubMed ID: 18559581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innovative strategies for early clinical R&D.
    Butz RF; Morelli G
    IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
    Marchetti S; Schellens JH
    Br J Cancer; 2007 Sep; 97(5):577-81. PubMed ID: 17726450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 0 trials: expediting the development of chemoprevention agents.
    Kummar S; Doroshow JH
    Cancer Prev Res (Phila); 2011 Mar; 4(3):288-92. PubMed ID: 21372025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory decision strategy for entry of a novel biological therapeutic with a clinically unmonitorable toxicity into clinical trials: pre-IND meetings and a case example.
    Black LE; Bendele AM; Bendele RA; Zack PM; Hamilton M
    Toxicol Pathol; 1999; 27(1):22-6. PubMed ID: 10367668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigational new drug application; exception from informed consent; technical amendment--FDA. Final rule.
    Fed Regist; 1997 Jun; 62(115):32479. PubMed ID: 10169828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Project Zero Delay: a process for accelerating the activation of cancer clinical trials.
    Kurzrock R; Pilat S; Bartolazzi M; Sanders D; Van Wart Hood J; Tucker SD; Webster K; Mallamaci MA; Strand S; Babcock E; Bast RC
    J Clin Oncol; 2009 Sep; 27(26):4433-40. PubMed ID: 19652061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.